Washington v. Edwards Lifesciences LLC

CourtDistrict Court, N.D. Texas
DecidedFebruary 13, 2025
Docket3:22-cv-02565
StatusUnknown

This text of Washington v. Edwards Lifesciences LLC (Washington v. Edwards Lifesciences LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Washington v. Edwards Lifesciences LLC, (N.D. Tex. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

LISA WASHINGTON, § § Plaintiff, § § v. § Civil Action No. 3:22-CV-02565-E § EDWARDS LIFESCIENCES LLC, § § Defendant. § § §

MEMORANDUM OPINION AND ORDER Before the Court are two motions for summary judgment. First, Plaintiff Lisa Washington’s Motion for Partial Summary Judgment seeks affirmative summary judgment on her Title VII claims of (i) failure to accommodate religious observance and (ii) religious discrimination. (ECF No. 38). Second, Defendant Edwards Lifesciences LLC’s (Edwards)’s Traditional and No Evidence Motion for Summary Judgment seeks summary judgment dismissal of all of Washington’s claims. (ECF No. 67). Additionally, the Parties have filed various ancillary motions that relate to these motions for summary judgment. Washington has moved for oral argument on her Motion for Partial Summary Judgment. (ECF No. 45). The Parties have filed various motions to strike based on (i) computation of time for filings1 and (ii) summary judgment evidence objections. (ECF Nos. 56; 70; 76; 84). Edwards has sought leave to file sur-reply on Washington’s Motion for Partial Summary Judgment. (ECF Nos. 59; 62; 63).

1 Federal Rule of Civil Procedure 6 enumerates the methods of computing time for filing motions. See generally Fed. R. Civ. P. 6. After considering the Parties’ briefing, appendices, and applicable law, the Court reaches the following adjudications. For the reasons hereunder, the Court: 1. DENIES Washington’s Motion for Partial Summary Judgment, (ECF No. 38); 2. GRANTS Edwards Lifesciences’s Traditional and No Evidence Motion for Summary Judgment, (ECF No. 67);

3. DENIES Washington’s motion for oral argument, (ECF No. 45); 4. DENIES Washington’s motion to strike Edwards’s motion for summary judgment based on computation of time, (ECF No. 70); 5. DENIES each motion to strike summary judgment evidence as moot, (ECF Nos. 56; 76; 84); 6. DENIES each motion to file sur-reply as moot, (ECF Nos. 59; 62; 63). I. BACKGROUND A. Edwards and Washington Edwards is a company that sells, inter alia, surgical heart valves. (ECF No. 69 at 20-23).

In 2001, Edwards hired Washington to sell surgical heart valves, tissue valves, mitral, and tricuspid repair rings. (ECF No. 69 at 11-12, 19-21). Washington’s job title changed over time, but her primary job duty was to promote the sale of these medical devices. (ECF No. 69 at 11-12, 19-21).2 Washington was responsible for: (i) identifying “growth opportunities” for Edwards; (ii) meeting sales quotas; (iii) launching new products; (iv) developing business opportunities; (v) continuing adoption of products with customers; and (vi) educating surgeons and hospital staff on the safe and effective use of Edwards’s products. (ECF No. 21-26).

2 This is the first-filed of two employment cases that involve a plaintiff that sold medical devices for Edwards. See Stark v. Edwards Lifesciences LLC, No. 3:22-CV-02579-E. Washington’s job description did not specify how or where these tasks are to be completed—whether in-hospital or outside-hospital. (ECF No. 69 at 94). Edwards required its salespersons—including Washington—to meet with customers both outside and inside hospital settings. (ECF No. 69 at 136-42). Washington communicated with surgeons by phone and text. (ECF No. 69 at 28). Washington presented products to surgeons one-on-one—either in their offices

or in the operating room. (ECF No. 28-29). For educating hospital staff, Washington set up “in[- ]service” meetings, which occurred inside and outside of the customer hospitals. (ECF No. 69 at 26-28). Washington hosted lectures outside of the customer hospitals. (ECF No. 69 at 26-28, 60). B. Edwards and COVID-19 Mandates In summer and fall of 2021, a new variant of COVID-19—the Delta variant—circulated throughout the United States. (ECF No. 69 at 108, 119-20, 123).3 Edwards’s Senior Vice President for Global Employee Health Dr. Tista Ghosh determined that this: Delta variant was causing more severe illness, particularly among the types of high- risk patients that Edwards treats. In addition, the Delta variant was found in a July 2021 study to be more contagious, reducing exposure time necessary to spread infection from minutes to seconds. In addition, an August 2021 study found that people had double the hospitalization risk with Delta than they did with the previously dominant variant.

(ECF No. 69 at 119). In response, Edwards implemented COVID-19 mandates for its employees, which involved vaccination or testing. Ghosh testified during her deposition that: We have the highest risk patients, and they all were at risk of potentially dying from COVID at that point. So we made this policy for people who potentially interacted with patients or went into hospital facilities, because our goal was to protect patients at that time. [. . .] [][D]uring that timeframe, we were still learning about a new variant called the delta variant[,] which had just come out that summer. And it was different. It was

3 See generally Alabama Ass’n of Realtors v. Dep’t of Health & Human Services, 594 U.S. 758, 772 (2021) (Breyer, J., dissenting) (discussing that the “Delta variant is more than 2x as contagious as previous variants” and may “cause more severe illness than previous strains in unvaccinated persons”) (internal quotation omitted). very different from the previous variants. And it was more contagious we were learning. We didn’t have a full picture at this point. [. . . .] Around September, we still didn’t have full data. Every day was different with -- with COVID at that point. We were getting so much new information every day. [. . . .] But at that point, we believed we were doing our best to protect our patients by [. . .] asking everyone to be vaccinated if they were going into patient types of settings. But if they couldn’t be vaccinated because of a religious exemption, for example, we put in extra safety measures. So we asked people to test twice a week by PCR, which is the gold standard, highest accuracy test for COVID. And wear an N-95 mask when going into these, you know, patient-related spaces in order to both accommodate the religious or medical exemption and keep our patients as safe as possible, because that was our number one goal.

(ECF No. 69 at 108-09) (emphasis added). Edwards implemented two mandates for its employees—the First Mandate and the Second Mandate—in response to the Delta variant of COVID-19. (ECF No. 69 at 123, 143-44). i. The First Mandate The August 30, 2021 First Mandate stated: After careful consideration, we have decided that all patient-facing and in- hospital employees and contingent workers must receive all required COVID vaccine doses[] by October 1 2021. This definition includes anyone who directly interfaces with patients and those who enter a hospital or healthcare facility as a part of their role. Examples include, but are not limited to, sales representatives, clinical specialists, and members based at an Edwards facility who enter hospitals to support R&D, engineering and clinical projects. [. . . .] This vaccination requirement does not apply to employees and contingent workers in countries where it is prohibited by law to impose vaccination. In countries like the United States, where vaccine requirements are permissible, reasonable accommodation will be provided for those who are unable to receive a COVID vaccine because of qualifying medical or religious reasons.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Forsyth v. Barr
19 F.3d 1527 (Fifth Circuit, 1994)
Little v. Liquid Air Corp.
37 F.3d 1069 (Fifth Circuit, 1994)
Woodson v. Surgitek, Inc.
57 F.3d 1406 (Fifth Circuit, 1995)
Eason v. Thaler
73 F.3d 1322 (Fifth Circuit, 1996)
Wallace v. Texas Tech Univ.
80 F.3d 1042 (Fifth Circuit, 1996)
Jones v. Sheehan, Young & Culp, P.C.
82 F.3d 1334 (Fifth Circuit, 1996)
Doddy v. Oxy USA, Inc.
101 F.3d 448 (Fifth Circuit, 1996)
Ragas v. Tennessee Gas Pipeline Co.
136 F.3d 455 (Fifth Circuit, 1998)
Bruff v. North Mississippi Health Services, Inc.
244 F.3d 495 (Fifth Circuit, 2001)
Rios v. Rossotti
252 F.3d 375 (Fifth Circuit, 2001)
Kapche v. City of San Antonio
304 F.3d 493 (Fifth Circuit, 2002)
Laxton v. Gap Inc.
333 F.3d 572 (Fifth Circuit, 2003)
Rachid v. Jack In The Box Inc
376 F.3d 305 (Fifth Circuit, 2004)
Keelan v. Majesco Software, Inc.
407 F.3d 332 (Fifth Circuit, 2005)
Abarca v. Metropolitan Transit Authority
404 F.3d 938 (Fifth Circuit, 2005)
Pacheco v. Mineta
448 F.3d 783 (Fifth Circuit, 2006)
Lorenz v. Wal-Mart Stores, Inc.
225 F. App'x 302 (Fifth Circuit, 2007)
Lee v. Kansas City Southern Railway Co.
574 F.3d 253 (Fifth Circuit, 2009)
Link v. Wabash Railroad
370 U.S. 626 (Supreme Court, 1962)

Cite This Page — Counsel Stack

Bluebook (online)
Washington v. Edwards Lifesciences LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/washington-v-edwards-lifesciences-llc-txnd-2025.